TCIM
PDSB icon

TIAA CREF Investment Management’s PDS Biotechnology PDSB Stock Holding History

TIAA CREF Investment Management’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-2,281
Closed -$54K – 3107
2018
Q1 		$54K Sell
2,281
-190
-8% -$51.1K ﹤0.01% 3026
2017
Q4 		$463K Sell
2,471
-92
-4% -$18.5K ﹤0.01% 2809
2017
Q3 		$550K Buy
2,563
+52
+2% +$10.8K ﹤0.01% 2785
2017
Q2 		$515K Buy
2,511
+286
+13% +$56.3K ﹤0.01% 2856
2017
Q1 		$405K Sell
2,225
-85
-4% -$16.8K ﹤0.01% 2862
2016
Q4 		$577K Buy
2,310
+47
+2% +$10.7K ﹤0.01% 2791
2016
Q3 		$471 Sell
2,263
-93
-4% -$18.4K ﹤0.01% 2872
2016
Q2 		$476K Buy
2,356
+1,472
+167% +$260K ﹤0.01% 2879
2016
Q1 		$162K Hold
884
– – ﹤0.01% 3008
2015
Q4 		$221K Buy
+884
New +$285K ﹤0.01% 3055

Other funds holding PDSB

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TIAA CREF Investment Management's PDSB Position: Q2 2018 in Review

TIAA CREF Investment Management sold out of PDS Biotechnology (PDSB) in Q2 2018, closing a stake of 2,281 shares — an estimated $54K sold.

TIAA CREF Investment Management first reported a position in PDSB in Q4 2015 and held it in 10 quarters. The position peaked at $577K in Q4 2016. 43 funds tracked by Wall St. Rank hold PDSB as of Q2 2018.

  • TIAA CREF Investment Management reported no remaining PDS Biotechnology position as of Q2 2018 after selling out during the quarter.
  • TIAA CREF Investment Management sold 2,281 PDS Biotechnology shares in Q2 2018, an estimated $54K.
  • TIAA CREF Investment Management first reported a position in PDS Biotechnology in Q4 2015 and held it in 10 quarters.
  • TIAA CREF Investment Management's PDS Biotechnology position peaked at $577K in Q4 2016.
  • 43 funds tracked by Wall St. Rank held PDS Biotechnology as of Q2 2018.

Based on TIAA CREF Investment Management's 13F filing for Q2 2018, filed 14 Aug 2018.